Centogene completes recruitment for EFRONT Study

Centogene announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia, or FTD. The EFRONT Study has been conducted with support from Alector, a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, including FTD. Having met this milestone, CENTOGENE will continue to work with its extensive network of 30,000 physicians and enroll patients in the EFRONT Study under its Cento-FTD Program to provide timely diagnosis and further unlock insights into this neurodegenerative disorder.